Scientists develop CAR-NKT cell therapy for ovarian cancer
A new type of immunotherapy called CAR-NKT cell therapy has been shown to be more effective at fighting ovarian cancer than conventional CAR-T cell therapy.
Unlike current cellular immunotherapies that require patient-specific manufacturing and can cost hundreds of thousands of dollars, CAR-NKT cells can be produced off-the-shelf, lowering costs to approximately $5,000 per dose.
The CAR-NKT platform shows promise for treating lung, brain and other solid tumours that have been challenging for CAR-T cell therapies to tackle.
“This is the culmination of over a decade of work in my lab and represents over six years of collaboration with gynaecologic oncologist Dr Sanaz Memarzadeh,” said co-senior author Lili Yang, a Professor of Microbiology, Immunology and Molecular Genetics and a member of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA. “We’re on the verge of clinical development, and I’m genuinely optimistic that this therapy could fundamentally change how we treat ovarian cancer.”
An off-the-shelf cancer therapy
CAR-T cell therapies have shown limited success against solid tumours, particularly ovarian cancer, due in part to its diverse cellular makeup and sophisticated defence systems. To overcome these challenges, the research team’s novel CAR-NKT cell therapy harnesses invariant natural killer T cells, or NKT cells.
While CAR-T cells recognise only one target on cancer cells, the research team noted these CAR-NKT cells can identify dozens of molecular markers. CAR-NKT cells can also better penetrate the protective barrier that shields ovarian tumours from conventional CAR-T cells.
When the team tested the novel CAR-NKT therapy on 35 ovarian patient-derived tumour samples, the CAR-NKT cells successfully killed ovarian cancer cells in every single sample — including samples from both newly diagnosed patients and patients whose cancers had recurred after chemotherapy.
“Our vision is to make CAR-NKT cells available as an off-the-shelf therapy at hospitals in the US and worldwide,” Yang said. “Instead of weeks-long delays for custom manufacturing, doctors could prescribe and access these cells immediately when patients need them most.”
Diana Turner, Senior Digital Content Editor, DDW
